Postpartum Depression - Market Insights, Epidemiology, and Market Forecast 2028
This report can be delivered to the clients within 7-10 Business Days
DelveInsight's “Postpartum Depression - Market Insights, Epidemiology and Market Forecast – 2028” report provides the detailed overview of the disease and in depth understanding of historical and forecasted Postpartum Depression epidemiology. It highlights the existing treatment patterns, potential upcoming Postpartum Depression drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028.
Markets Covered
Postpartum Depression Understanding and Treatment Algorithm
The Postpartum Depression market report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Postpartum Depression in the US, Europe, and Japan are also provided in the report.
Postpartum Depression Epidemiology
This section provide the insights about historical and current Postpartum Depression patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.
Postpartum Depression Product Profiles & Analysis
This part of the report encloses the detailed analysis of Postpartum Depression marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.
Postpartum Depression Market Outlook
The Postpartum Depression market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight. Postpartum Depression Market Share by Therapies
This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.
Postpartum Depression Report Insights
DelveInsight's “Postpartum Depression - Market Insights, Epidemiology and Market Forecast – 2028” report provides the detailed overview of the disease and in depth understanding of historical and forecasted Postpartum Depression epidemiology. It highlights the existing treatment patterns, potential upcoming Postpartum Depression drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2017-2028.
Markets Covered
- United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan
Postpartum Depression Understanding and Treatment Algorithm
The Postpartum Depression market report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Postpartum Depression in the US, Europe, and Japan are also provided in the report.
Postpartum Depression Epidemiology
This section provide the insights about historical and current Postpartum Depression patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies, survey reports as well as KOL’s views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.
Postpartum Depression Product Profiles & Analysis
This part of the report encloses the detailed analysis of Postpartum Depression marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.
Postpartum Depression Market Outlook
The Postpartum Depression market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight. Postpartum Depression Market Share by Therapies
This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.
Postpartum Depression Report Insights
- Postpartum Depression Patient Population
- Postpartum Depression Therapeutic Approaches
- Postpartum Depression Pipeline Analysis
- Postpartum Depression Market Size and Trends
- Postpartum Depression Market Opportunities
- Impact of upcoming Therapies in Postpartum Depression
- Postpartum Depression 10 Year Forecast
- Postpartum Depression 7MM Coverage
- Postpartum Depression Epidemiology Segmentation
- Postpartum Depression Drugs Uptake
- Highly Analyzed Postpartum Depression Market
- Key Cross Competition
- Current Treatment Practices in Postpartum Depression
- Postpartum Depression Unmet Needs
- Detailed Postpartum Depression Pipeline Product Profiles
- Postpartum Depression Market Attractiveness
- Postpartum Depression Market Drivers and Barriers
- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Postpartum Depression market
- Organize sales and marketing efforts by identifying the best opportunities for Postpartum Depression market
- To understand the future market competition in the Postpartum Depression market.
1. REPORT INTRODUCTION
2. POSTPARTUM DEPRESSION MARKET OVERVIEW AT A GLANCE
2.1. Market Share Distribution of Postpartum Depression in 2017
2.2. Market Share Distribution of Postpartum Depression in 2028
3. DISEASE BACKGROUND AND OVERVIEW: POSTPARTUM DEPRESSION
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Postpartum Depression in 7MM
4.3. Total Prevalent Patient Population of Postpartum Depression in 7MM – By Countries
5. EPIDEMIOLOGY OF POSTPARTUM DEPRESSION BY COUNTRIES
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Postpartum Depression
5.1.3. Sub-Type Specific cases of the Postpartum Depression *Indication Specific
5.1.4. Sex- Specific Cases of the Postpartum Depression *Indication Specific
5.1.5. Diagnosed Cases of the Postpartum Depression
5.1.6. Treatable Cases of the Postpartum Depression
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Postpartum Depression
5.4.3. Sub-Type Specific cases of the Postpartum Depression *
5.4.4. Sex- Specific Cases of the Postpartum Depression *
5.4.5. Diagnosed Cases of the Postpartum Depression
5.4.6. Treatable Cases of the Postpartum Depression
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Postpartum Depression
5.5.3. Sub-Type Specific cases of the Postpartum Depression *
5.5.4. Sex- Specific Cases of the Postpartum Depression *
5.5.5. Diagnosed Cases of the Postpartum Depression
5.5.6. Treatable Cases of the Postpartum Depression
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Postpartum Depression
5.6.3. Sub-Type Specific cases of the Postpartum Depression *
5.6.4. Sex- Specific Cases of the Postpartum Depression *
5.6.5. Diagnosed Cases of the Postpartum Depression
5.6.6. Treatable Cases of the Postpartum Depression
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Postpartum Depression
5.7.3. Sub-Type Specific cases of the Postpartum Depression *
5.7.4. Sex- Specific Cases of the Postpartum Depression *
5.7.5. Diagnosed Cases of the Postpartum Depression
5.7.6. Treatable Cases of the Postpartum Depression
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Postpartum Depression
5.8.3. Sub-Type Specific cases of the Postpartum Depression *
5.8.4. Sex- Specific Cases of the Postpartum Depression *
5.8.5. Diagnosed Cases of the Postpartum Depression
5.8.6. Treatable Cases of the Postpartum Depression
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Postpartum Depression
5.9.3. Sub-Type Specific cases of the Postpartum Depression *
5.9.4. Sex- Specific Cases of the Postpartum Depression *
5.9.5. Diagnosed Cases of the Postpartum Depression
5.9.6. Treatable Cases of the Postpartum Depression
6. CURRENT TREATMENT & MEDICAL PRACTICES
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. UNMET NEEDS OF THE POSTPARTUM DEPRESSION
8. MARKETED THERAPIES
8.1. Drug A: Company
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. PIPELINE THERAPIES – AT A GLANCE
10. KEY CROSS COMPETITION
11. EMERGING THERAPIES FOR POSTPARTUM DEPRESSION
11.1. Drug C: Company
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. POSTPARTUM DEPRESSION : 7MM MARKET ANALYSIS
12.1. 7MM Market Size of Postpartum Depression
12.2. 7MM Percentage Share of drugs marketed for Postpartum Depression
12.3. 7MM Market Sales of Postpartum Depression by Products
13. POSTPARTUM DEPRESSION : COUNTRY-WISE MARKET ANALYSIS
13.1. United States
13.1.1. Market Size of Postpartum Depression in United States
13.1.2. Percentage Share of drugs marketed for Postpartum Depression in United States
13.1.3. Market Sales of Postpartum Depression by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Postpartum Depression in Germany
13.2.1.2. Percentage Share of drugs marketed for Postpartum Depression in Germany
13.2.1.3. Market Sales of Postpartum Depression by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Postpartum Depression in France
13.2.2.2. Percentage Share of drugs marketed for Postpartum Depression in France
13.2.2.3. Market Sales of Postpartum Depression by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Postpartum Depression in Italy
13.2.3.2. Percentage Share of drugs marketed for Postpartum Depression in Italy
13.2.3.3. Market Sales of Postpartum Depression by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Postpartum Depression in Spain
13.2.4.2. Percentage Share of drugs marketed for Postpartum Depression in Spain
13.2.4.3. Market Sales of Postpartum Depression by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Postpartum Depression in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Postpartum Depression in United Kingdom
13.2.5.3. Market Sales of Postpartum Depression by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Postpartum Depression in Japan
13.3.2. Percentage Share of drugs marketed for Postpartum Depression in Japan
13.3.3. Market Sales of Postpartum Depression by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
17. REPORT METHODOLOGY
17.1. Sources
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
2. POSTPARTUM DEPRESSION MARKET OVERVIEW AT A GLANCE
2.1. Market Share Distribution of Postpartum Depression in 2017
2.2. Market Share Distribution of Postpartum Depression in 2028
3. DISEASE BACKGROUND AND OVERVIEW: POSTPARTUM DEPRESSION
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Postpartum Depression in 7MM
4.3. Total Prevalent Patient Population of Postpartum Depression in 7MM – By Countries
5. EPIDEMIOLOGY OF POSTPARTUM DEPRESSION BY COUNTRIES
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Postpartum Depression
5.1.3. Sub-Type Specific cases of the Postpartum Depression *Indication Specific
5.1.4. Sex- Specific Cases of the Postpartum Depression *Indication Specific
5.1.5. Diagnosed Cases of the Postpartum Depression
5.1.6. Treatable Cases of the Postpartum Depression
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Postpartum Depression
5.4.3. Sub-Type Specific cases of the Postpartum Depression *
5.4.4. Sex- Specific Cases of the Postpartum Depression *
5.4.5. Diagnosed Cases of the Postpartum Depression
5.4.6. Treatable Cases of the Postpartum Depression
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Postpartum Depression
5.5.3. Sub-Type Specific cases of the Postpartum Depression *
5.5.4. Sex- Specific Cases of the Postpartum Depression *
5.5.5. Diagnosed Cases of the Postpartum Depression
5.5.6. Treatable Cases of the Postpartum Depression
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Postpartum Depression
5.6.3. Sub-Type Specific cases of the Postpartum Depression *
5.6.4. Sex- Specific Cases of the Postpartum Depression *
5.6.5. Diagnosed Cases of the Postpartum Depression
5.6.6. Treatable Cases of the Postpartum Depression
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Postpartum Depression
5.7.3. Sub-Type Specific cases of the Postpartum Depression *
5.7.4. Sex- Specific Cases of the Postpartum Depression *
5.7.5. Diagnosed Cases of the Postpartum Depression
5.7.6. Treatable Cases of the Postpartum Depression
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Postpartum Depression
5.8.3. Sub-Type Specific cases of the Postpartum Depression *
5.8.4. Sex- Specific Cases of the Postpartum Depression *
5.8.5. Diagnosed Cases of the Postpartum Depression
5.8.6. Treatable Cases of the Postpartum Depression
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Postpartum Depression
5.9.3. Sub-Type Specific cases of the Postpartum Depression *
5.9.4. Sex- Specific Cases of the Postpartum Depression *
5.9.5. Diagnosed Cases of the Postpartum Depression
5.9.6. Treatable Cases of the Postpartum Depression
6. CURRENT TREATMENT & MEDICAL PRACTICES
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. UNMET NEEDS OF THE POSTPARTUM DEPRESSION
8. MARKETED THERAPIES
8.1. Drug A: Company
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. PIPELINE THERAPIES – AT A GLANCE
10. KEY CROSS COMPETITION
11. EMERGING THERAPIES FOR POSTPARTUM DEPRESSION
11.1. Drug C: Company
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. POSTPARTUM DEPRESSION : 7MM MARKET ANALYSIS
12.1. 7MM Market Size of Postpartum Depression
12.2. 7MM Percentage Share of drugs marketed for Postpartum Depression
12.3. 7MM Market Sales of Postpartum Depression by Products
13. POSTPARTUM DEPRESSION : COUNTRY-WISE MARKET ANALYSIS
13.1. United States
13.1.1. Market Size of Postpartum Depression in United States
13.1.2. Percentage Share of drugs marketed for Postpartum Depression in United States
13.1.3. Market Sales of Postpartum Depression by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Postpartum Depression in Germany
13.2.1.2. Percentage Share of drugs marketed for Postpartum Depression in Germany
13.2.1.3. Market Sales of Postpartum Depression by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Postpartum Depression in France
13.2.2.2. Percentage Share of drugs marketed for Postpartum Depression in France
13.2.2.3. Market Sales of Postpartum Depression by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Postpartum Depression in Italy
13.2.3.2. Percentage Share of drugs marketed for Postpartum Depression in Italy
13.2.3.3. Market Sales of Postpartum Depression by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Postpartum Depression in Spain
13.2.4.2. Percentage Share of drugs marketed for Postpartum Depression in Spain
13.2.4.3. Market Sales of Postpartum Depression by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Postpartum Depression in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Postpartum Depression in United Kingdom
13.2.5.3. Market Sales of Postpartum Depression by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Postpartum Depression in Japan
13.3.2. Percentage Share of drugs marketed for Postpartum Depression in Japan
13.3.3. Market Sales of Postpartum Depression by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
17. REPORT METHODOLOGY
17.1. Sources
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
LIST OF TABLES
Table 1: Total Prevalent/Incident Cases of the Postpartum Depression in 7MM
Table 2: Total Prevalent/Incident Cases of the Postpartum Depression in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Postpartum Depression in United States (2017-2028)
Table 4: Sub-Type Specific cases of the Postpartum Depression in United States (2017-2028)
Table 5: Sex- Specific Cases of the Postpartum Depression in United States (2017-2028)
Table 6: Diagnosed Cases of the Postpartum Depression in United States (2017-2028)
Table 7: Treatable Cases of the Postpartum Depression in United States (2017-2028)
Table 8: Prevalent/Incident Cases of the Postpartum Depression in Germany (2017-2028)
Table 9: Sub-Type Specific cases of the Postpartum Depression in Germany (2017-2028)
Table 10: Sex- Specific Cases of the Postpartum Depression in Germany (2017-2028)
Table 11: Diagnosed Cases of the Postpartum Depression in Germany (2017-2028)
Table 12: Treatable Cases of the Postpartum Depression in Germany (2017-2028)
Table 13: Prevalent/Incident Cases of the Postpartum Depression in France (2017-2028)
Table 14: Sub-Type Specific cases of the Postpartum Depression in France (2017-2028)
Table 15: Sex- Specific Cases of the Postpartum Depression in France (2017-2028)
Table 16: Diagnosed Cases of the Postpartum Depression in France (2017-2028)
Table 17: Treatable Cases of the Postpartum Depression in France (2017-2028)
Table 18: Prevalent/Incident Cases of the Postpartum Depression in Italy (2017-2028)
Table 19: Sub-Type Specific cases of the Postpartum Depression in Italy (2017-2028)
Table 20: Sex- Specific Cases of the Postpartum Depression in Italy (2017-2028)
Table 21: Diagnosed Cases of the Postpartum Depression in Italy (2017-2028)
Table 22: Treatable Cases of the Postpartum Depression in Italy (2017-2028)
Table 23: Prevalent/Incident Cases of the Postpartum Depression in Spain (2017-2028)
Table 24: Sub-Type Specific cases of the Postpartum Depression in Spain (2017-2028)
Table 25: Sex- Specific Cases of the Postpartum Depression in Spain (2017-2028)
Table 26: Diagnosed Cases of the Postpartum Depression in Spain (2017-2028)
Table 27: Treatable Cases of the Postpartum Depression in Spain (2017-2028)
Table 28: Prevalent/Incident Cases of the Postpartum Depression in UK (2017-2028)
Table 29: Sub-Type Specific cases of the Postpartum Depression in UK (2017-2028)
Table 30: Sex- Specific Cases of the Postpartum Depression in UK (2017-2028)
Table 31: Diagnosed Cases of the Postpartum Depression in UK (2017-2028)
Table 32: Treatable Cases of the Postpartum Depression in UK (2017-2028)
Table 33: Prevalent/Incident Cases of the Postpartum Depression in Japan (2017-2028)
Table 34: Sub-Type Specific cases of the Postpartum Depression in Japan (2017-2028)
Table 35: Sex- Specific Cases of the Postpartum Depression in Japan (2017-2028)
Table 36: Diagnosed Cases of the Postpartum Depression in Japan (2017-2028)
Table 37: Treatable Cases of the Postpartum Depression in Japan (2017-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Postpartum Depression in USD MM (2017-2028)
Table 42:7MM- Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 43:7MM- Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 44: United States-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 45: United States-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 46: United States-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 47: Germany-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 48: Germany-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 49: Germany-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 50: France-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 51: France-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 52: France-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 53: Italy-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 54: Italy-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 55: Italy-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 56: Spain-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 57: Spain-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 58: Spain-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 59:UK-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 60:UK-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 61:UK-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 62: Japan-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 63: Japan-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 64: Japan-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 1: Total Prevalent/Incident Cases of the Postpartum Depression in 7MM
Table 2: Total Prevalent/Incident Cases of the Postpartum Depression in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Postpartum Depression in United States (2017-2028)
Table 4: Sub-Type Specific cases of the Postpartum Depression in United States (2017-2028)
Table 5: Sex- Specific Cases of the Postpartum Depression in United States (2017-2028)
Table 6: Diagnosed Cases of the Postpartum Depression in United States (2017-2028)
Table 7: Treatable Cases of the Postpartum Depression in United States (2017-2028)
Table 8: Prevalent/Incident Cases of the Postpartum Depression in Germany (2017-2028)
Table 9: Sub-Type Specific cases of the Postpartum Depression in Germany (2017-2028)
Table 10: Sex- Specific Cases of the Postpartum Depression in Germany (2017-2028)
Table 11: Diagnosed Cases of the Postpartum Depression in Germany (2017-2028)
Table 12: Treatable Cases of the Postpartum Depression in Germany (2017-2028)
Table 13: Prevalent/Incident Cases of the Postpartum Depression in France (2017-2028)
Table 14: Sub-Type Specific cases of the Postpartum Depression in France (2017-2028)
Table 15: Sex- Specific Cases of the Postpartum Depression in France (2017-2028)
Table 16: Diagnosed Cases of the Postpartum Depression in France (2017-2028)
Table 17: Treatable Cases of the Postpartum Depression in France (2017-2028)
Table 18: Prevalent/Incident Cases of the Postpartum Depression in Italy (2017-2028)
Table 19: Sub-Type Specific cases of the Postpartum Depression in Italy (2017-2028)
Table 20: Sex- Specific Cases of the Postpartum Depression in Italy (2017-2028)
Table 21: Diagnosed Cases of the Postpartum Depression in Italy (2017-2028)
Table 22: Treatable Cases of the Postpartum Depression in Italy (2017-2028)
Table 23: Prevalent/Incident Cases of the Postpartum Depression in Spain (2017-2028)
Table 24: Sub-Type Specific cases of the Postpartum Depression in Spain (2017-2028)
Table 25: Sex- Specific Cases of the Postpartum Depression in Spain (2017-2028)
Table 26: Diagnosed Cases of the Postpartum Depression in Spain (2017-2028)
Table 27: Treatable Cases of the Postpartum Depression in Spain (2017-2028)
Table 28: Prevalent/Incident Cases of the Postpartum Depression in UK (2017-2028)
Table 29: Sub-Type Specific cases of the Postpartum Depression in UK (2017-2028)
Table 30: Sex- Specific Cases of the Postpartum Depression in UK (2017-2028)
Table 31: Diagnosed Cases of the Postpartum Depression in UK (2017-2028)
Table 32: Treatable Cases of the Postpartum Depression in UK (2017-2028)
Table 33: Prevalent/Incident Cases of the Postpartum Depression in Japan (2017-2028)
Table 34: Sub-Type Specific cases of the Postpartum Depression in Japan (2017-2028)
Table 35: Sex- Specific Cases of the Postpartum Depression in Japan (2017-2028)
Table 36: Diagnosed Cases of the Postpartum Depression in Japan (2017-2028)
Table 37: Treatable Cases of the Postpartum Depression in Japan (2017-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Postpartum Depression in USD MM (2017-2028)
Table 42:7MM- Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 43:7MM- Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 44: United States-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 45: United States-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 46: United States-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 47: Germany-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 48: Germany-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 49: Germany-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 50: France-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 51: France-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 52: France-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 53: Italy-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 54: Italy-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 55: Italy-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 56: Spain-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 57: Spain-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 58: Spain-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 59:UK-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 60:UK-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 61:UK-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Table 62: Japan-Market Size of Postpartum Depression in USD MM (2017-2028)
Table 63: Japan-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Table 64: Japan-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
LIST OF FIGURES
Figure 1: Total Prevalent/Incident Cases of the Postpartum Depression in 7MM
Figure 2: Total Prevalent/Incident Cases of the Postpartum Depression in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Postpartum Depression in United States (2017-2028)
Figure 4: Sub-Type Specific cases of the Postpartum Depression in United States (2017-2028)
Figure 5: Sex- Specific Cases of the Postpartum Depression in United States (2017-2028)
Figure 6: Diagnosed Cases of the Postpartum Depression in United States (2017-2028)
Figure 7: Treatable Cases of the Postpartum Depression in United States (2017-2028)
Figure 8: Prevalent/Incident Cases of the Postpartum Depression in Germany (2017-2028)
Figure 9: Sub-Type Specific cases of the Postpartum Depression in Germany (2017-2028)
Figure 10: Sex- Specific Cases of the Postpartum Depression in Germany (2017-2028)
Figure 11: Diagnosed Cases of the Postpartum Depression in Germany (2017-2028)
Figure 12: Treatable Cases of the Postpartum Depression in Germany (2017-2028)
Figure 13: Prevalent/Incident Cases of the Postpartum Depression in France (2017-2028)
Figure 14: Sub-Type Specific cases of the Postpartum Depression in France (2017-2028)
Figure 15: Sex- Specific Cases of the Postpartum Depression in France (2017-2028)
Figure 16: Diagnosed Cases of the Postpartum Depression in France (2017-2028)
Figure 17: Treatable Cases of the Postpartum Depression in France (2017-2028)
Figure 18: Prevalent/Incident Cases of the Postpartum Depression in Italy (2017-2028)
Figure 19: Sub-Type Specific cases of the Postpartum Depression in Italy (2017-2028)
Figure 20: Sex- Specific Cases of the Postpartum Depression in Italy (2017-2028)
Figure 21: Diagnosed Cases of the Postpartum Depression in Italy (2017-2028)
Figure 22: Treatable Cases of the Postpartum Depression in Italy (2017-2028)
Figure 23: Prevalent/Incident Cases of the Postpartum Depression in Spain (2017-2028)
Figure 24: Sub-Type Specific cases of the Postpartum Depression in Spain (2017-2028)
Figure 25: Sex- Specific Cases of the Postpartum Depression in Spain (2017-2028)
Figure 26: Diagnosed Cases of the Postpartum Depression in Spain (2017-2028)
Figure 27: Treatable Cases of the Postpartum Depression in Spain (2017-2028)
Figure 28: Prevalent/Incident Cases of the Postpartum Depression in UK (2017-2028)
Figure 29: Sub-Type Specific cases of the Postpartum Depression in UK (2017-2028)
Figure 30: Sex- Specific Cases of the Postpartum Depression in UK (2017-2028)
Figure 31: Diagnosed Cases of the Postpartum Depression in UK (2017-2028)
Figure 32: Treatable Cases of the Postpartum Depression in UK (2017-2028)
Figure 33: Prevalent/Incident Cases of the Postpartum Depression in Japan (2017-2028)
Figure 34: Sub-Type Specific cases of the Postpartum Depression in Japan (2017-2028)
Figure 35: Sex- Specific Cases of the Postpartum Depression in Japan (2017-2028)
Figure 36: Diagnosed Cases of the Postpartum Depression in Japan (2017-2028)
Figure 37: Treatable Cases of the Postpartum Depression in Japan (2017-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 42:7MM- Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 43:7MM- Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 44: United States-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 45: United States-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 46: United States-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 47: Germany-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 48: Germany-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 49: Germany-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 50: France-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 51: France-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 52: France-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 53: Italy-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 54: Italy-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 55: Italy-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 56: Spain-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 57: Spain-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 58: Spain-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 59:UK-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 60:UK-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 61:UK-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 62: Japan-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 63: Japan-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 64: Japan-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 1: Total Prevalent/Incident Cases of the Postpartum Depression in 7MM
Figure 2: Total Prevalent/Incident Cases of the Postpartum Depression in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Postpartum Depression in United States (2017-2028)
Figure 4: Sub-Type Specific cases of the Postpartum Depression in United States (2017-2028)
Figure 5: Sex- Specific Cases of the Postpartum Depression in United States (2017-2028)
Figure 6: Diagnosed Cases of the Postpartum Depression in United States (2017-2028)
Figure 7: Treatable Cases of the Postpartum Depression in United States (2017-2028)
Figure 8: Prevalent/Incident Cases of the Postpartum Depression in Germany (2017-2028)
Figure 9: Sub-Type Specific cases of the Postpartum Depression in Germany (2017-2028)
Figure 10: Sex- Specific Cases of the Postpartum Depression in Germany (2017-2028)
Figure 11: Diagnosed Cases of the Postpartum Depression in Germany (2017-2028)
Figure 12: Treatable Cases of the Postpartum Depression in Germany (2017-2028)
Figure 13: Prevalent/Incident Cases of the Postpartum Depression in France (2017-2028)
Figure 14: Sub-Type Specific cases of the Postpartum Depression in France (2017-2028)
Figure 15: Sex- Specific Cases of the Postpartum Depression in France (2017-2028)
Figure 16: Diagnosed Cases of the Postpartum Depression in France (2017-2028)
Figure 17: Treatable Cases of the Postpartum Depression in France (2017-2028)
Figure 18: Prevalent/Incident Cases of the Postpartum Depression in Italy (2017-2028)
Figure 19: Sub-Type Specific cases of the Postpartum Depression in Italy (2017-2028)
Figure 20: Sex- Specific Cases of the Postpartum Depression in Italy (2017-2028)
Figure 21: Diagnosed Cases of the Postpartum Depression in Italy (2017-2028)
Figure 22: Treatable Cases of the Postpartum Depression in Italy (2017-2028)
Figure 23: Prevalent/Incident Cases of the Postpartum Depression in Spain (2017-2028)
Figure 24: Sub-Type Specific cases of the Postpartum Depression in Spain (2017-2028)
Figure 25: Sex- Specific Cases of the Postpartum Depression in Spain (2017-2028)
Figure 26: Diagnosed Cases of the Postpartum Depression in Spain (2017-2028)
Figure 27: Treatable Cases of the Postpartum Depression in Spain (2017-2028)
Figure 28: Prevalent/Incident Cases of the Postpartum Depression in UK (2017-2028)
Figure 29: Sub-Type Specific cases of the Postpartum Depression in UK (2017-2028)
Figure 30: Sex- Specific Cases of the Postpartum Depression in UK (2017-2028)
Figure 31: Diagnosed Cases of the Postpartum Depression in UK (2017-2028)
Figure 32: Treatable Cases of the Postpartum Depression in UK (2017-2028)
Figure 33: Prevalent/Incident Cases of the Postpartum Depression in Japan (2017-2028)
Figure 34: Sub-Type Specific cases of the Postpartum Depression in Japan (2017-2028)
Figure 35: Sex- Specific Cases of the Postpartum Depression in Japan (2017-2028)
Figure 36: Diagnosed Cases of the Postpartum Depression in Japan (2017-2028)
Figure 37: Treatable Cases of the Postpartum Depression in Japan (2017-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 42:7MM- Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 43:7MM- Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 44: United States-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 45: United States-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 46: United States-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 47: Germany-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 48: Germany-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 49: Germany-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 50: France-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 51: France-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 52: France-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 53: Italy-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 54: Italy-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 55: Italy-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 56: Spain-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 57: Spain-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 58: Spain-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 59:UK-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 60:UK-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 61:UK-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 62: Japan-Market Size of Postpartum Depression in USD MM (2017-2028)
Figure 63: Japan-Market Share Postpartum Depression by Therapies in USD MM (2017-2028)
Figure 64: Japan-Market Sales of Postpartum Depression by Therapies in USD MM (2017-2028)
